(Revised from the previ- ous guideline) Measures to control BP should begin immediately after ICH onset (Class I; Level of Evidence A). (New recommendation) A long-term goal of BP <130 mmHg systolic and 80 mmHg diastolic is reasonable (Class IIa; Level of Evidence B). (New recommendation) Lifestyle modifications, including avoidance of alco- hol use greater than 2 drinks per day, tobacco use, and illicit drug use, as well as treatment of obstruc- tive sleep apnea, are probably beneficial (Class IIa; Level of Evidence B). (Revised from previous guideline) Avoidance of long-term anticoagulation with warfa- rin as a treatment for nonvalvular atrial fibrillation is probably recommended after warfarin-associated spontaneous lobar ICH because of the relatively high risk of recurrence (Class IIa; Level of Evidence B). (Unchanged from the previous guideline) Anticoagulation after nonlobar ICH and antiplate- let monotherapy after any ICH might be considered, particularly when there are strong indications for these agents (Class IIb; Level of Evidence B). (Revised from the previous guideline) The optimal timing to resume oral anticoagula- tion after anticoagulant-related ICH is uncertain. Avoidance of oral anticoagulation for at least 4 weeks, in patients without mechanical heart valves, might decrease the risk of ICH recurrence (Class IIb; Level of Evidence B). (New recommendation) If indicated, aspirin monotherapy can probably be restarted in the days after ICH, although the optimal timing is uncertain (Class IIa; Level of Evidence B). (New recommendation) The usefulness of dabigatran, rivaroxaban, or apixa- ban in patients with atrial fibrillation and past ICH to decrease the risk of recurrence is uncertain (Class IIb; Level of Evidence C). (New recommendation) There are insufficient data to recommend restric- tions on the use of statins in ICH patients (Class IIb; Level of Evidence C). 